Table I. Clinico-pathological characteristics of patients for tissue mass spectrometry and IHC studies.
| Clinical factors | Discovery cohort |
Validation cohort |
Discovery vs. validation |
||||
|---|---|---|---|---|---|---|---|
| HPV− (n = 26) | HPV+ (n = 27) | p value | HPV− (n = 17) | HPV+ (n = 12) | p value | p value | |
| Age (median, range) | 67 (33–80) | 67 (41–83) | 0.94 | 69 (43–93) | 69 (35–84) | 0.82 | 0.48 |
| Sex (male/female) | 22/4 | 20/7 | 0.50 | 15/2 | 12/0 | 0.50 | 0.12 |
| Stage | 0.08 | 0.26 | 0.99 | ||||
| I | 1 | 0 | 0 | 0 | |||
| II | 3 | 2 | 3 | 0 | |||
| III | 7 | 2 | 3 | 3 | |||
| IVA | 10 | 20 | 10 | 6 | |||
| IVB | 5 | 3 | 1 | 3 | |||
| Treatment | 0.20 | 1.00 | 0.44 | ||||
| RT | 18 | 14 | 12 | 8 | |||
| CRT | 8 | 13 | 5 | 4 | |||
Notes: RT, radiotherapy alone; CRT, chemo-radiotherapy.